Pfizer Inc. Files 8-K on Shareholder Votes

TL;DR

Pfizer filed an 8-K on shareholder votes, standard corporate update.

AI Summary

Pfizer Inc. filed an 8-K on April 28, 2025, reporting on matters submitted to a vote of security holders as of April 24, 2025. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31). It also lists the company's principal executive offices located at 66 Hudson Boulevard East, New York, NY.

Why It Matters

This filing provides transparency regarding corporate governance and shareholder decisions at Pfizer Inc., which can influence investor confidence and company strategy.

Risk Assessment

Risk Level: low — This is a routine corporate filing detailing a vote of security holders and does not indicate any unusual financial or operational risks.

Key Numbers

• 1231 — Fiscal Year End (Indicates the end of Pfizer's annual financial reporting period.)
• 20250424 — Date of Earliest Event Reported (The date on which the reported event (submission to vote) occurred.)

Key Players & Entities

• Pfizer Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• New York (location) — Principal executive offices city
• 66 Hudson Boulevard East (address) — Principal executive offices street

FAQ

From the Filing

0000078003-25-000109.txt : 20250428 0000078003-25-000109.hdr.sgml : 20250428 20250428162401 ACCESSION NUMBER: 0000078003-25-000109 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250424 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250428 DATE AS OF CHANGE: 20250428 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 25880726 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20250424.htm 8-K pfe-20250424 0000078003 false 0000078003 2024-04-25 2024-04-25 0000078003 us-gaap:CommonStockMember 2024-04-25 2024-04-25 0000078003 pfe:NotesDue20271.000Member 2024-04-25 2024-04-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 24, 2025 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 5.07 Submission of Matters to a Vote of Security Holders (a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 24, 2025. (b) Shareholders voted on the matters set forth below. 1. The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 13, 2025 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes: Nominee Votes For       Votes Against Abstentions Broke